Monoclonal antibodies, derived from humans vaccinated with the RV144 HIV vaccine containing the HVEM binding domain of herpes simplex virus (HSV) glycoprotein D, neutralize HSV infection, mediate antibody-dependent cellular cytotoxicity, and protect mice from ocular challenge with HSV-1

Author(s):

Kening Wang, Georgia D. Tomaras, Sinthujan Jegaskanda, M. Anthony Moody, Hua Xin Liao, Kyle N. Goodman, Phillip W. Berman, Supachai Rerks-Ngarm, Punnee Pitisuttithum, Sorachai Nitayapan, Jaranit Kaewkungwal, Barton F. Haynes, Jeffrey I. Cohena

Details:

Journal of Virology, Volume 91, Issue 19, 2017-10-01, Article number e00411-17

Article Link: Click here

Affiliations:

• Duke University School of Medicine
• National Institute of Allergy and Infectious Diseases (NIAID)
• Baskin School of Engineering
• Faculty of Tropical Medicine, Mahidol University
• Department of Microbiology & Immunology
• Thailand Ministry of Public Health
• Royal Thai Army